| Publisher’s Note: We are thrilled to announce First Lady Jill Biden will be joining us as a keynote speaker at Fierce JPM Week in San Francisco on January 14th. |
|
This report examines market factors shaping leukemia, lymphoma, and myeloma pipelines. Discover effective strategies to overcome these evolving challenges. Download for free. +(002)+140w.png)
|
|
Today’s Big NewsJan 9, 2025 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
| By James Waldron Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has arrived on the scene with an eye-popping series A. |
|
|
|
By Nick Paul Taylor Bayer’s hot flash drug candidate has hit the mark in a phase 3 breast cancer trial, potentially positioning the German drugmaker to get the jump on Astellas’ rival drug Veozah. |
By Fraiser Kansteiner Under a new licensing pact, Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an undisclosed but agreed upon number of cancer targets. At the same time, Synaffix has also inked a technology licensing deal with Japan's Mitsubishi Tanabe Pharma. |
Sponsored by Astellas Pharma Inc. Discover how Astellas builds innovation partnerships with ambitious organizations that share their vision to transform the lives of patients |
|
Life sciences companies face the challenge of meeting today’s performance, innovation, and competitive requirements while preparing for the unknown. Access this report to learn how to adopt the right approaches to achieve true organizational transformation by leveraging a wide array of data sources alongside a digitization strategy. Download now. 
|
|
By James Waldron Velia Therapeutics is winding down its operations while staying loyal to the therapeutic potential of microproteins. |
By Darren Incorvaia It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from pursuing new drugs of its own for the devastating neurological disease. The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS. |
By Darren Incorvaia Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a spokesperson confirmed to Fierce Biotech in an email. |
By Nick Paul Taylor A phase 3 trial of MaaT Pharma’s graft-versus-host disease drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid-2025. |
By Fraiser Kansteiner Earlier this week, a study of Astellas’ autologous CAR-T asset ASP2802 in CD20-positive B-cell lymphomas was listed as terminated in the U.S.’ online clinical trial database. Astellas confirmed that it has stopped development on the candidate, which it attributed to "prioritization efforts." |
By James Waldron Despite its dwindling cash reserves, Windtree has announced a bold new strategy—trying to acquire small biotechs with FDA-approved products. |
By Gabrielle Masson,Darren Incorvaia The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Gabrielle Masson After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, M.D., is calling out the regulatory agency for a “disturbing pattern of conduct” that “harms the American public.” |
By James Waldron Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to license a Chinese biotech’s IgA nephropathy antibody. |
By Angus Liu When the BIOSECURE Act missed the chance of becoming law in 2024, the deceleration of the draft legislation invited the question of whether two biotechs living under the shadow of the bill—Legend Biotech and BeiGene—should grasp the opportunity and seek an exit in 2025. |
By Conor Hale Johnson & Johnson MedTech announced that it has paused U.S. procedures and sales of its recently approved Varipulse pulsed field ablation system following reports of four patient strokes. |
Fierce podcasts Don’t miss an episode |
| Fierce Healthcare hosted the second annual Fierce Health Payer Summit in November. Top leaders and decision-makers in the healthcare and payer industry convened in Austin, Texas, for two days of discussions. |
|
|---|
|
|
|
Gene therapies are growing fast, but they have one big challenge ahead: making them at a commercial scale. Access this report for an important look at the critical requirements that gene therapy manufacturers should assess when starting their custom reagent journey. Download today! 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
